Svetlana Nikic, Founder of Precision Oncology Consulting and Strategic Advisor at 2Strands Biosciences, shared a post on LinkedIn by Kimary Kulig, Founder of My Biomarker Navigator, adding:
“Still, over one-third of women with breast or ovarian cancer are not tested for germline BRCA mutations (US data, I believe, but EU numbers will most likely be the same).
This gap means missed opportunities for genetic counseling, preventive interventions, and family risk assessment.”
Quoting Kimary Kulig’s post shared from Ed Esplin, Clinical Geneticist, Medical Officer at Invitae:”
“This has to change!”
Quoting Ed Esplin’s post about a paper by Lu Shi et al. published in Breast Cancer Research and Treatment:
“Only 50% and 47% of women with breast cancer and ovarian cancer, respectively, had germline genetic testing and utilization was slightly lower in 2021 vs 2019 and 2020, despite the American Society of Breast Surgeons and National Comprehensive Cancer Network (NCCN) recs for universal germline testing
…failure to test is predominantly due to physicians’ lack of awareness…and problems with the genetic counseling and testing process.
…findings suggest lower genetic testing rates among Asian and Black women
This must change, now.”
Title: BRCA testing utilization among commercially insured women with breast or ovarian cancer
Authors: Lu Shi, Katherine Kolor, Zhuo Chen, Ramal Moonesinghe, Juan Rodriguez, Muin J. Khoury, Scott D. Grosse
You can read the Full Article in Breast Cancer Research and Treatment.
More posts featuring Svetlana Nikic.